Stocktoria
DarioHealth Corp. DRIO
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2013-03-08
DarioHealth Corp. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.4M | $27.0M | $20.4M | $27.7M | $20.5M | $7.6M | $7.6M | $7.4M | $5.2M | $2.8M |
| Gross profit | $12.7M | $13.3M | $6.0M | $9.7M | $4.0M | $2.5M | $2.6M | $1.8M | $1.3M | -$830,000 |
| R&D expense | $13.8M | $24.2M | $20.2M | $19.6M | $17.2M | $4.4M | $3.7M | $3.7M | $3.3M | $2.2M |
| Operating income | -$36.7M | -$57.7M | -$56.2M | -$56.8M | -$76.5M | -$29.9M | -$17.7M | -$17.7M | -$14.4M | -$11.1M |
| Income tax | $105,000 | -$1.9M | $64,000 | $4,000 | $32,000 | — | — | — | — | — |
| Net income | -$41.7M | -$42.7M | -$59.4M | -$62.2M | -$76.8M | -$29.4M | -$17.7M | -$17.8M | -$15.7M | -$10.9M |
| EPS (diluted) | $10.12 | $12.27 | $1.93 | $2.54 | $4.07 | $4.01 | — | — | — | — |
| Operating cash flow | -$25.9M | -$38.6M | -$30.4M | -$47.8M | -$50.4M | -$17.7M | -$15.7M | -$11.5M | -$10.6M | -$8.4M |
| Free cash flow | -$26.1M | -$38.7M | -$31.0M | -$48.3M | -$50.7M | -$17.9M | -$15.8M | -$11.5M | -$10.8M | -$9.2M |
| Cash & equivalents | $21.8M | $27.8M | $36.8M | $49.4M | $35.8M | $28.6M | $20.4M | $11.0M | $3.7M | $1.1M |
| Inventory | $4.3M | $4.8M | $5.1M | $8.0M | $6.2M | $2.3M | $1.4M | $1.4M | $1.2M | $888,000 |
| Total assets | $110.1M | $118.9M | $96.4M | $119.2M | $100.8M | $35.4M | $24.6M | $14.1M | $7.0M | $3.9M |
| Shareholders' equity | $67.9M | $72.0M | $58.1M | $80.0M | $85.5M | $28.2M | $18.9M | $8.9M | $3.9M | -$6.5M |
Growth · year-over-year · Revenue CAGR 26%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -17.3% | +32.9% | -26.4% | +34.8% | +170.8% | +0.2% | +2.2% | +43.0% | +84.4% | +240.6% |
| EPS growth | -17.5% | +535.8% | -24.0% | -37.6% | +1.5% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.